Shengkai Innovations, Inc. (Nasdaq:VALV) today announced financial results for its fourth quarter and fiscal year 2011. Highlights: Fourth Quarter Revenues increased 70.9% yoy to approximately $27.3 million; Revenues from the electric power segment increased 48.8% yoy to approximately $15.0 million; Revenues from the petrochemical and chemical segment increased 68.8% yoy to approximately $8.4 million; Revenues […]
SIGA Technologies, Inc. (SIGA) shares tanked hard on news that a Delaware court of Chancery had ruled in favour of PharmAthene (PIP) in a dispute involving SIGA‘s smallpox drug ST-246. 50% of the net profits that SIGA will be achieving from sales of ST-246 awarded to PharmAthene for the next ten years. Harsh decision, isn’t it? […]
JA Solar Holdings Co., Ltd. (JASO), manufacturer of high-performance solar power products, today gained 12.5% on 9,904,092 shares in trading volume vs 7,339,210 10day average. First uptrend signal after months of downtrend, isn’t it? To make long story short: read respectful opinions on JA Solar Holdings (excerpt & links are below), browse JASO‘s yahoo finance […]
Tree.Com, Inc. (NASDAQ: TREE) today released Form 8-K that sale of some of its assets from the former company’s real estate segment to Market Leader, Inc. has been completed. Market might react favorable to this news considering the latest TREE‘s actions for recovering from previous company’s consumer market refinancing mistakes. Just for reminder: TREE‘s stock […]
RXi Pharmaceuticals Corp. (RXII) announced today that The U.S. Food and Drug administration has cleared the CMC partial clinical hold, allowing the pivotal Phase 3 trial of NeuVax to commence. NeuVax is expected to initiate its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) […]
Equities research analysts at Lazard Capital initiated coverage on shares of AVI BioPharma (NASDAQ: AVII) in a research note issued to investors on Thursday. They set a “buy” rating and a $5.00 price target on the stock. Lazard Capital Markets is full service broker-dealer. Lazard’s Capital research covers the following Healthcare (BioPharma) companies: Aegerion NeurogesX Alkermes […]
Remember What Insiders Know, and We Don’t ? We profiled Headwaters Inc. (NYSE: HW) on August 22nd at $1.80/share as the NYSE stock market bounce play based on its insider transactions (stock buys on open market). HW hit our target at $2.20 just in 6 trading sessions. Do you mind to put on your watchlist […]
Tower Semiconductor Ltd. (TSEM) announced today that its fully owned Japanese subsidiary TowerJazz Japan, LTD. signed a Memorandum of Understanding (MOU) with Samsung Electro-Mechanics to develop and volume produce a variety of product families based on TowerJazz’s 700V (TS100PM) power management process. The first products are expected to be in the market in the second […]
OXiGENE, Inc. (OXGN) announced restructuring of its clinical programs & new focus of the company: Phase 3 registrational study of ZYBRESTAT in patients with anaplastic thyroid cancer & Phase 2 ZYBRESTAT trial in non-small cell lung cancer have been put on hold. Investigator-sponsored Phase 1 trial of OXi4503 in patients with AML or myelodysplastic syndrome […]
NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (Zelrix). PATH shares plunged to $2.06 at pre-market trading hours. PATH traded over 5.7M shares compared to 204K 10day average volume. Our […]
